Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Press releases

Sequana Medical to host webcast on 27 May 2019

Company to discuss late-breaking abstract of DSR therapy for volume overload in heart failure presented at the Heart Failure 2019 Congress Ghent, BELGIUM – 21 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart...

Sequana Medical announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis

Further validation builds on U.S. FDA[1] Breakthrough Device status and inclusion in U.K. NICE[2] recommendations and EASL[3] guidelines   Ghent, BELGIUM – 15 May 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant...

Sequana Medical announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress

Ghent, BELGIUM – 30 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that results from the first-in-human single dose DSR (Direct Sodium Removal)...

Sequana Medical announces Annual General Meeting of Shareholders on 23 May 2019

Regulated Information Ghent, BELGIUM – 23 April 2019 (18:00 CEST) – Sequana Medical NV (“Sequana Medical” or the “Company“) (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces that its Annual...

Sequana Medical announces 2018 Full Year Results and 2019 Outlook

Ghent, BELGIUM – 4 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces its business highlights and financial results for the year ended 31 December 2018, prepared...

Sequana Medical Notice of 2018 Full Year Results and 2019 Outlook

Ghent, BELGIUM – 28 March 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, will announce its results for the full year ended 31 December 2018 and outlook for 2019...

Extraordinary General Shareholders’ Meeting to be held on 25 April 2019

Regulated Information Ghent, BELGIUM – 26 March 2019 (19:00 CET) – Sequana Medical NV [Euronext Brussels: SEQUA] (“Sequana Medical”, the “Company”) today invited the holders of securities issued by the Company to attend an extraordinary shareholders’ meeting before notary public on Thursday 25 April 2019. The agenda items of the extraordinary shareholders’ meeting relate to...

Sequana Medical announces the end of the stabilisation period of its offering

Ghent, BELGIUM – 18 March 2019 (5.30 PM CET) – Today, Sequana Medical NV (“Sequana Medical” or the “Company“), announces the end of the stabilisation period in the framework of the initial public offering of new shares of the Company with the admission of all of its shares to trading on the regulated market of...

Mid Stabilisation Period Announcement

Ghent, BELGIUM – 1 March 2019 – Within the framework of the initial public offering of new shares of Sequana Medical NV (“Sequana Medical” or the “Company“), with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “SEQUA” (the “Offering“), KBC Securities NV/SA has been...

Transparency Notifications from Shareholders

Ghent, BELGIUM – 25 February 2019 – Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today in accordance with article 14 of the Belgian Act of...
1 12 13 14 15 16 17

Subscribe to our Press Releases

    PRESS RELEASES

    SUBSCRIBE TO OUR PRESS RELEASES